Consideration
99 In the end, KMA's case rested on the proposition that I should accept - essentially at face value - Mr Zheng's assertion in paragraph [3] of his 13 April 2022 affidavit that "it was the intention of Erbaviva to use, or authorise the use, in Australia of the … KANGAROO MOTHER [Mark] in respect of the following the [sic] goods in Classes 5, 29, 30, 31 and 32 the subject of the Application, details of which are set out in the print-out of that Application from the Australian Trade Marks Office database attached and marked Annexure AFZ-1".
100 I say "in the end" because KMA produced on discovery and put in its tender bundle a number of documents that were said to be relevant to Erbaviva's intention to use or authorise the use of the KANGAROO MOTHER Mark in relation to the relevant classes of goods. One such document was an unsigned non-disclosure agreement between NZ Skin Care and a company called Delta Laboratories Pty Ltd, bearing the date 6 March 2019. Leaving aside the obvious enough difficulty that the agreement was entered into by NZ Skin Care, not Erbaviva, the list of products included within the scope of the non-disclosure agreement concerned cosmetics - not foodstuffs, beverages or supplements, or any of the Designated Goods, a point accepted by Mr Zheng in this passage of cross-examination:
Now, you remember you discovered this document as a document relevant to whether Erbaviva had an intention to use or authorise the use of the Kangaroo Mother mark in relation to the classes of goods we've seen before, yes? Yes.
Yes. Let's go to page 10. These are the products that Ms Yin had put on the NDA. First, we see cleansing? Yes.
Toning water? Yes.
Lotion? That's right.
Cream, essence, eye cream, face masks and massage oil? Yes.
It's pretty clear, isn't it, that these are all personal care products? Yes.
Skin care products, aren't they? Yes.
They don't fit within any of the classes we've been talking about, do they? For some of products - some of the products, they may be classified as class 5, if they're medical or for medical purposes. But, again, like, I wasn't part of the discussion between Emily Yin and this manufacturer, so I - I wasn't sure, you know, what the discussion was about. But I agree with you in principle. Like, most of them - they were personal care and, you know, preparations for - for cosmetics.
101 The evidence that KMA ultimately sought to rely on in support of the proposition that it was Erbaviva's intention to use, or authorise the use, in Australia of the trade mark KANGAROO MOTHER in respect of the goods in the list which Mr Zheng provided to Mr Sullivan on 14 February 2019, alternatively all of the Designated Goods, is this:
(1) On 12 February 2019, at 7.02pm, Ms Yin emailed Mr Zheng saying that Mr Liu "mentioned" that "we" should "apply for a food trade mark with Kangaroo Mother, and in the future we may focus on designing nutritional supplements such as DHA/folic acid".
(2) The brochure attached for Mr Zheng's "reference" contained information about product ranges that included "gel candies", "pressed candies", "drops", "powdered dairy products", "solid beverages" and "capsules".
(3) By 8.19pm the same day - just a little more than an hour after Mr Yin's first email - and having "cut and pasted" lengthy descriptions of different goods in classes 5, 29, 30, 31 and 32 from the IPONZ website, Mr Zheng told Ms Yin that he planned to register them all.
102 KMA also made these brief submissions in its written closing submission:
In respect of the Class 3 goods, the evidence demonstrated advanced plans in respect of skincare range, ingredients, negotiations with Delta Laboratories and also, preparation of draft packaging: Exhibits AXB-42 - 46.
In respect of the Class 5 goods, the evidence demonstrated consideration of a Unipharm Brochure for supplements and/or health food products: Exhibit AXB-27 and Exhibit AXB-28.
Other preparatory steps were taken, such as the establishment of KMA itself, an email account (Exhibit R3, Exhibit R4); and account with GS1 for obtaining product barcodes: Exhibit R10.
103 There a number of difficulties with KMA's submission that I should accept at face value Mr Zheng's assertion in paragraph [3] of his 13 April 2022 affidavit. In particular, as the correspondence shows, and as Mr Zheng had to concede, Mr Sullivan filed the application with IP Australia with a significantly broader range of goods than the list he instructed be filed. So to the extent that Mr Zheng asserted in his affidavit and insisted in cross-examination (see the passage from his cross-examination at paragraph [96] above) that he and therefore Erbaviva intended to use, or authorise the use, in Australia of the KANGAROO MOTHER Mark in respect of goods he had not instructed be included in the application, the assertion must be rejected because it is nonsensical.
104 But even if one were to accept KMA's submission that Mr Zheng's assertion in his affidavit should be read instead as an assertion that it was Erbaviva's intention to use, or authorise the use, in Australia of the KANGAROO MOTHER MARK in respect of the goods in the list which he provided to Mr Sullivan, all of the relevant evidence is to the contrary.
105 First, Mr Zheng agreed in cross-examination that he did not take the email from Ms Lin about DHA/folic acid as an instruction from Mr Liu to develop DHA.
106 Secondly, there was no evidence of any documentation, plan or proposal for any intended use that went beyond the gel candies, pressed candies, drops, powdered dairy products, solid beverages or capsules mentioned in the brochure attached to Ms Yin's email.
107 Thirdly, Mr Zheng's proposal for an application for registration of the KANGAROO MOTHER Mark was, on his own evidence, conjured in a matter of minutes by cutting and pasting from the IPONZ website. As EB submitted, it was obviously speculative and went beyond anything that could even remotely be said to have been the subject of an intention to use of any kind, let alone a "real and definite intention" of the type necessary. See Goodman Fielder Pte Ltd v Conga Foods Pty Ltd [2020] FCA 1808; (2020) 158 IPR 9 at 37 [119] (Burley J); Health World Limited v Shin-Sun Australia Pty Ltd [2008] FCA 100; 75 IPR 478 at 497 [160].
108 Fourthly, it is also relevant that since filing the application for the KANGAROO MOTHER Mark well over four years ago, neither Erbaviva nor KMA has manufactured or attempted to have manufactured any of the Designated Goods. Compare Goodman Fielder Pte Ltd v Conga Foods Pty Ltd [2020] FCA 1808; (2020) 158 IPR 9 at 38 [125] ("a failure to use after the filing date may enable a Court to infer that there was a lack of intention").
109 In re-examination, in the passage set out at paragraph [98] above, Mr Zheng said that was because of the dispute the subject of this proceeding. Mr Zheng's newly minted reason in re-examination was unconvincing, and I do not accept it. Among other things, as EB submitted in closing:
[The trade mark] dispute did not commence until 16 December 2019, and did not stop Ms Yin or Ms Deng from making preparations to commence using "Kangaroo Mother" or the like in respect of cosmetics, even before the registration of that mark had been granted.
110 KMA's next contention was that Shanghai Urganic, Erbaviva and Mr Zheng operated as a "conglomerate" in relation to the so-called the KANGAROO MOTHER brand and trade marks generally, and that in some way the actions of other entities and entities were relevant to the question of intention to use under s 59.
111 The submission was put this way in KMA's written submissions:
The Conglomerate or "Group" of Shanghai Urganic are companies that within the group had direct ownership, a shareholding relationship, the same senior management and/or the same investors. Companies in the Group included various entities including KMA, Erbaviva, NZ Skin Care and Urganic New Zealand.
Given that the companies in the Group are in the consumer product industry and deal with the same target audience, they often work together and share resources including channels, suppliers, personnel, investors and skillsets.
112 It was never explained what any of that amounted to as a matter of legal principle.
113 And the only evidence cited in closing in support of the "conglomerate" submission was the following passage from Mr Zheng's re-examination:
In a number of your answers, Mr Zheng, you referred to "the conglomerate" or "the group"? Yes.
What are the companies that you consider to form part of the conglomerate, or group? They are companies that within the group had direct ownership or a shareholding relationship. For example, Shanghai Urganic, Urganic New Zealand, New Zealand Skin Care. But there are other groups - group companies that are slightly more remote but have the same senior management or same investors behind. So, you know, we don't formally call ourselves a group because of various reasons, you know, and to avoid, for example, conflicts between the investors behind. But, you know, because we are all in this consumer product industry and we are dealing with the same target audience. So we often work together and share resources, you know, channels, suppliers, etcetera. Sometimes even personnel or investors, you know. So that's what I meant by … the group.
114 I must confess, and intending no disrespect to Mr Zheng, that answer is incomprehensible.
115 As to KMA's submissions set out at paragraph [102] above, they are also to no avail, because the exhibits there cited have nothing to do with Erbaviva. They are emails from Ms Yin to Mr Zheng from NZ Skin Care and NZ Skin Care (AXB 27 and AXB 28); emails between Mr Zheng and Ms Deng and others (AXB 42 and AXB 43) and emails from Ms Deng to Mr Zheng using the email address emilydeng2011@foxmail.com (AXB 44 and 45). Further, the emails are dated between February and August 2020, over a year after KMA's application was filed.
116 And AXB 46 is a List of Documents, so that is of no use.
117 And "the establishment of KMA itself, an email account (Exhibit R3, Exhibit R4); and account with GS1 for obtaining product barcodes (Exhibit R10)" self-evidently do not evidence an intention to use the KANGAROO MOTHER Mark.
118 The relevant intention as to use for s 59 purposes can only be ascribed, in a case such as this, to the entity that made the application for the mark - here, Erbaviva and its sole guiding mind, Mr Zheng.
119 If it is sought to contend that beliefs or opinions or states of mind of others are to be attributed to that guiding mind and thus the applicant corporate entity, "it is necessary to specify some person or persons so closely and relevantly connected with the company that the state of mind of that person or those persons can be treated as being identified with the company so that their state of mind can be treated as being the state of mind of the company". See Brambles Holdings Ltd v Carey (1976) 15 SASR 270 at 279 (Bright J), cited with approval in Krakowski v Eurolynx Properties Ltd (1995) 183 CLR 563 at 582-3 (Brennan, Deane, Gaudron and McHugh JJ).
120 There is not a skerrick of evidence to suggest that the state of mind of KMA, NZ Skin Care, Urganic New Zealand, or Mr Liu, Ms Deng or Ms Lin, "can be treated as the state of mind" of Erbaviva.
121 As EB submitted, and I agree:
In the case of a single director company, owned by that director, with no employees other than the director, that director must hold the intent to use or authorise the use of the trade mark. That company's intention cannot be evidenced by a third party's intention, or activity, which has not itself been adopted, or directed by, respectively, the director.
122 Relatedly, KMA also relied on cases about a so-called "unity of purpose" of companies in a group, with common directors exerting some degree of group control, citing Trident Seafoods Corporation v Trident Foods Pty Ltd [2019] FCAFC 100; (2019) 369 ALR 367 at 380 [46] (Reeves, Jagot and Rangiah JJ); and RB (Hygiene Home) Australia Pty Ltd v Henkel Australia Pty Ltd [2022] FCA 1042; (2022) 168 IPR 293 at 330 [207]-[209] (Rofe J).
123 KMA made the following submission about "unity of purpose":
Importantly, at all material times Mr Zheng was a director of three companies Erbaviva, KMA and NZ Skin Care Company Limited. It was Mr Zheng that was responsible for filing the trade mark applications in the name of Erbaviva, instructing his trade mark attorneys and developing the brand with the assistance of individuals that were either directors, shareholders or employed by the Group.
The documentary evidence shows that Chairman Liu, and Shanghai Urganic employees, Emily Deng and Emily Lim, together with Mr Zheng, established a certain degree of group-wide control in the areas of marketing and product development of the KANGAROO MOTHER brand.
The Court would infer a "unity of purpose" between the individuals responsible for developing the KANGAROO MOTHER brand and accordingly, that the intention to use and authorise the use of Erbaviva at the time priority date is established.
124 It would be obvious from what I have already said that the submission cannot be accepted.
125 It was not in dispute that Mr Zheng was the sole guiding mind of KMA. And even to accept, for the sake of the argument, that Mr Lui, unnamed Urganic employees, Ms Deng and Ms Lim and Mr Zheng "established a certain degree of group-wide control in the areas of marketing and product development of the KANGAROO MOTHER brand" leads nowhere, including because the proposition does not purport to be connected to, and does not even mention, the filing of the relevant trade mark application or the use of any mark.
126 EB also submitted that KMA did not intend as at the priority date to assign the mark to a body corporate (here, KMA) for use by it in Australia in relation to the Designated Goods. See s 59(b) of the Trade Marks Act.
127 Mr Zheng did not advert to any intention to assign the mark for use in relation to any of the Designated Goods in his 13 April 2022 affidavit. He went no further than the incantation "it was the intention of Erbaviva to … authorise the use … of the trade mark". EB submitted that it was not now open to KMA to contend that it did intend as at the priority date to assign the mark to KMA.
128 KMA contended that they had not abandoned the point, and that in his emails to AJ Park dated 4 September 2017 and 14 February 2019 respectively (see paragraphs [72] and [90] above), Mr Zheng referred to an Australian entity holding the mark once it was registered, and that reliance on such evidence from the outset of the trial meant that KMA could still rely on the point. I do not accept that submission, because Mr Zheng did not depose as to Erbaviva's intention as at the priority date to authorise KMA to use the KANGAROO MOTHER Mark in relation to the, or any of the, Designated Goods.
129 But even if I am wrong about that, and the incantation suffices, and KMA were permitted now to contend that Erbaviva's did intend as at the priority date to assign the KANGAROO MOTHER Mark to KMA for use by it in relation to the Designated Goods, the evidence demonstrates to the contrary.
130 In that regard, Mr Cordiner relied on the following exchange with Mr Zheng in the context of cross-examination about why he had agreed with Ms Lin that NZ Skin Care - and not Erbaviva - was proposed as the party to sign the non-disclosure agreement with Delta Laboratories Pty Ltd (see paragraph [99] above):
[D]o you agree with me that there's no email from you responding and saying, "That's the wrong entity. It should be Erbaviva"? No. There was - I didn't - I didn't send an email to her saying - suggesting that was the wrong entity.
Really? Because, in fact, the company which would be - which was always intended to do this kind of work would be New Zealand Skin Care; is that right? No. The company we actually wanted to use is Kangaroo Mother, but I don't think it was established properly at that time, so we - we needed someone [to] enter the NDA with - with the … laboratory, and - because … New Zealand Skin Care is a - is our, well, so-called biggest entity here in Australasia and New Zealand, so I assume that's why Emily proposed that we used New Zealand Skin Care.
131 Mr Cordiner made the following oral submission arising from that evidence, which indicates that Mr Zheng at that point (March 2019) intended that if any entity intended to use or authorise the use of the KANGAROO mark it was NZ Skin Care, not Erbaviva:
If [Mr Zheng] didn't have the intention to use or authorise the use for Erbaviva to use or authorise the use, then we say there can't have been any intention on top of that from the evidence to have some unidentified future company be assigned the mark and use it. So we don't - we say it's not open for our friends to rely on 59(1)(b), but even if it was, it doesn't take them there.
132 That must, with respect, follow and I accept that submission.
133 For those reasons, I find on the evidence, that as at 15 February 2019, Erbaviva had no intention to use or authorise the use of the KANGAROO MOTHER Mark in respect of any of Designated Goods within the meaning of s 59 and that EB's ground of opposition under that section is made out.
134 It follows that the appeal is to be allowed, and orders made that the decision of the Delegate be set aside and, in lieu thereof, the application for registration of the KANGAROO MOTHER Mark be refused.
135 Although it is strictly speaking unnecessary to do so, I will now deal with the other grounds of opposition contained in the notice of appeal, in case there is a successful appeal in relation to my finding in relation to s 59.